Mankind Pharma Q1 FY27 Earnings Call: Guides 25.5-26.5% EBITDA Margin, Chronic Mix Target at 50%

Mankind Pharma Ltd held its Q1 FY27 earnings call on July 30, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue, Profitability & Cash Flow Highlights

• Revenue of Rs.4,031 crore in Q1 FY 2026-2027, up 12.9% YoY (vs Rs.3,570 crore in Q1 FY 2025-2026), driven by strong BSV specialty business and 29% international growth.
• EBITDA of Rs.1,060 crore with margin of 26.3%, expanding 250 bps YoY (Q1 FY 2025-2026: 23.8%), aided by 230 bps from gross margin expansion and 20 bps from operating leverage.
• PAT grew 29.1% YoY to Rs.574 crore, with PAT margin at 14.2% (up 170 bps YoY); partially offset by a higher effective tax rate of 25.4% (Q1 FY 2025-2026: 17.7%) due to adoption of the new tax regime after the Sikkim plant exemption expired.
• Gross margin of 72.8% expanded 230 bps YoY, supported by price increases, better chronic mix (+120 bps YoY), and a favourable base from inventory accruals; management expects compression in Q2 FY 2026-2027 from higher commodity and dollar costs.
• Diluted EPS of Rs.13.7; cash EPS (adjusted for D&A) of Rs.19.2, up 20.8% YoY; total depreciation of Rs.225 crore, with ~50% acquisition-related.
• Net debt reduced to Rs.3,377 crore as of 30 Jun 2026, with net debt-to-adjusted EBITDA ratio at 0.9x; management reiterated target to fully repay acquisition-related debt by FY 2027-2028.
• R&D spend of Rs.98 crore (2.4% of sales) in Q1 FY 2026-2027, below the full-year FY 2026-2027 guidance of 2.8%–3%; capex of Rs.198 crore (4.9% of revenue), also below the FY 2026-2027 guidance of 6%–7%.
• Net operating working capital of 52 days on a trailing 12-month basis (Q1 FY 2025-2026: 48 days), elevated due to higher inventory; cash flow to EBITDA ratio declined to 77% (Q1 FY 2025-2026: 99%) from higher tax, working capital changes, and base effects.

Sequential Improvement in Acute and Chronic Therapies

• Domestic business revenue of Rs.3,426 crore in Q1 FY 2026-2027, up 10.5% YoY; ex-consumer healthcare domestic revenue stood at Rs.3,180 crore, up 11% YoY.
• Secondary sales per IQVIA grew 12.7% in Q1 FY 2026-2027, led by volume growth of 4.7% (up 220 bps YoY from 2.5% in FY 2025-2026).
• Acute therapy growth improved to 10.9% in Q1 FY 2026-2027 from 3.3% in Q2 FY 2025-2026, now in line with the industry; sequential recovery seen across gastro (–2.5% → 13.6%), vitamins (5% → 19.3%), RyNaG (6.9% → 12.7%), and ophthalmology (6.2% → 17.5%).
• Chronic therapy growth accelerated to 15.8% in Q1 FY 2026-2027 from 12.2% in Q2 FY 2025-2026, with cardiac at 19.4% and anti-diabetes at 12.7%; respiratory remained above 20% for four consecutive quarters.
• Gynecology grew 12.7% YoY (ahead of IPM's 12.1%), led by 39% growth in the IBS portfolio (Polygraph, Hemo) and 20% growth in Dydroboon (1.5x market); VMN grew 19.3% YoY.
• Anti-infectives recovered to 3.6% YoY in Q1 FY 2026-2027 from 1.1% in Q4 FY 2025-2026; management attributed past acute underperformance to a deep correction 18 months ago involving personnel changes, with recovery expected to be gradual but on a stronger foundation.
• Attrition and vacancies have dropped significantly and are back to normal levels, enabling sequential improvement in doctor visits and sales force productivity.

Chronic Mix Expansion and Brand-Level Outperformance

• Chronic portfolio share (ex-BSB) reached 40% in Q1 FY 2026-2027, up 80 bps YoY; management targets chronic share at 50% in the medium term.
• Cardiac portfolio grew 19.4% YoY, outperforming IPM by 1.1x; Telmikind family grew ~21%, Lipikind 30%, and Statpure 31% in Q1 FY 2026-2027.
• Anti-diabetes (ex-teneligliptin) outperformed IPM by 1.1x; the Glyciphage brand family delivered 29% YoY growth in Q1 FY 2026-2027.
• Mankind's covered market in anti-diabetics improved from 56% in FY 2020-2021 to 74% in FY 2025-2026, with its rank rising from 10th to 7th and a market share of 4.5%.
• Prescription share remained #1 at 15.2% in Q1 FY 2026-2027, sustaining the leadership position.
• Excluding tirzepatide, Mankind outperformed the anti-diabetic segment by 1.2–1.3x; however, new launch (NI) contribution was only 2.8% vs IPM's 4.1% in Q1 FY 2026-2027, partly explaining the growth gap.
• Management aspires to return to historical outperformance of IPM by 1.3x to 1.7x, but stated it is "not in a hurry" and expects improvement quarter by quarter through structural drivers: chronic mix expansion, hospital business scaling, new division rollout, and underperforming region uplift.

Modern Trade and E-Commerce Gains Offset General Trade Softness

• Consumer healthcare revenue of Rs.246 crore in Q1 FY 2026-2027, growing only 3.8% YoY, impacted by the discontinuation of the cash-and-carry business which affected general trade.
• Modern trade and e-commerce share rose to 15% from 11% a year ago, supported by 38% channel growth in Q1 FY 2026-2027; management noted that e-commerce and modern trade are taking share from general trade.
• Market share gains in key consumer brands: Mankind improved share in the condom category, pregnancy test (Prega News), and antacid (Gasofast) segments despite a softer overall consumer market.
• Management guided consumer healthcare growth of "high single digit to double digit" from Q2 FY 2026-2027 onwards, citing recovery in the underlying brand performance.
• General trade was impacted by adjustments to the cash-and-carry business model; management described the overall consumer market as "dynamic" with structural shifts toward modern trade and e-commerce.

GLP-1 Strategy, New Launches, CNS Entry, and AI Partnership

• Semaglutide launch delayed intentionally due to a strategic shift in focus toward correcting the overall company rather than being among the first wave of 20–30 players; significant price drops from intense competition were cited as a key reason for not engaging in a price war.
• Mankind has already launched semaglutide in two segments as of Q1 FY 2026-2027: anti-diabetes and gynae, but expects a gradual takeoff due to "hyper-competition" and ongoing price wars; no export strategy for semaglutide.
• Rajeev Juneja described the GLP-1 approach as "strategic" rather than cautious: waiting for the market to settle before launching a complete therapy (including supplements); over 20 companies and 35+ brands are already in the GLP-1 space.
• Revotril brand acquired from Roche with annual IQVIA sales of Rs.20–30 crore (period unspecified), providing entry to multiple specialists in the CNS category; management stated that a Rs.100–200 crore aspiration exists but growth will take time given the specialist nature of CNS.
• New division "Vista" launched to scale lesser-focused brands in multi-specialty; partnered with Denovo Science for an AI-led drug discovery program.
• Selective new launch strategy emphasized building large brands: in Q1 FY 2026-2027, Gonaprazan (Bona Long) became the #1 brand and Empagliflozin was within the top three among new launches.

Export Growth, BSB Performance, and FY 2026-2027 Outlook

• International business revenue grew 29% YoY to Rs.605 crore in Q1 FY 2026-2027; export business (Mankind Pharma + BSB) grew in line with full-year "high teens" constant currency guidance.
• BSB grew 25% in Q1 FY 2026-2027, with domestic BSB at +17% and international BSB at +25%; currency tailwind added 12–13% in the quarter; BSB's domestic-to-international mix for FY 2026-2027 is expected to be 50–50 (±2%), consistent with the prior year.
• BSB growth guidance for FY 2026-2027 is "high teens", with the business run independently; initiatives include expanding gynaec coverage from 33,000 (FY 2024-2025) to 37,000, activating IVF programs (over 80% coverage, growing 35%+), and conducting clinical trials for key brands.
• Domestic business FY 2026-2027 guidance: "double digit" revenue growth, with sequential recovery, improvement in chronic segment, and recovery in acute business as demonstrated in Q1.
• EBITDA margin guidance for FY 2026-2027: 25.5%–26.5% (unchanged); gross margin guidance of 71% (upward of 71% per guidance), with the West Asia crisis cited as the only reason for conservatism relative to an earlier view of 71.5%.
• One-off benefit from a key ophthalmic product in the US entered the base in FY 2024-2025 and normalized in FY 2025-2026, so it no longer distorts export growth rates in FY 2026-2027.
• Net debt target: fully repay acquisition-related debt by FY 2027-2028; management also guided for improvement in working capital days in the coming quarters.